Sugi Predict

Sugi Predict / Compounds / SCHEMBL1122902

SCHEMBL1122902

SCHEMBL1122902

COc1ccc(N)c(OC)c1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.50
▸ EP300 Q09472 1/20 0.48
▸ KAT8 Q9H7Z6 1/20 0.48
▸ ALDH1A1 P00352 6/20 0.48
▸ CYP3A4 P08684 3/20 0.48
▸ TDP1 Q9NUW8 3/20 0.48
▸ TSHR P16473 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ CYP19A1 P11511 1/20 0.47
▸ ADRA2B P18089 1/20 0.46
▸ PTGS1 P23219 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ TUBB4A P04350 4/20 0.45
▸ TUBB P07437 4/20 0.45
▸ TUBA3C P0DPH7 4/20 0.45
▸ TUBA1B P68363 4/20 0.45
▸ TUBA4A P68366 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL28127438 0.98 IDO1 (0.48) IDO1EP300KAT8ALDH1A1CYP3A4
Hydrochloric Acid SCHEMBL6667575 0.98 EP300 (0.52) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL28366576 0.87 ALDH1A1 (0.46) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL3674074 0.84 CA9 (0.50) ALDH1A1CYP3A4TDP1CYP19A1MAPT
SCHEMBL30701949 0.84 CA9 (0.50) ALDH1A1CYP3A4TDP1CYP19A1MAPT
SCHEMBL455551 0.83 IDO1 (0.48) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL32670765 0.83 IDO1 (0.48) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL9455828 0.83 IDO1 (0.48) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL29452826 0.83 IDO1 (0.48) IDO1EP300KAT8ALDH1A1CYP3A4
SCHEMBL25009959 0.81 ALDH1A1 (0.48) IDO1EP300KAT8ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115960325-B Ultrathin chiral fluorescent covalent organic framework nano-sheet and preparation method and application thereof 中国科学院福建物质结构研究所 2024-11-12 — — CN claimed
CN-118367143-A Composite binder and application thereof 上海兰钧新能源科技有限公司 2024-07-19 — — CN claimed
CN-115960325-A Ultrathin chiral fluorescent covalent organic framework nanosheet and preparation method and application thereof 中国科学院福建物质结构研究所 2023-04-14 — — CN claimed
US-20030199694-A1 Thermally stable trimetrexates and processes for producing the same MEDIMMUNE ONCOLOGY, INC. 2003-10-23 — — US claimed
US-20020107393-A1 Tremextrexate derivatives and pharmaceutical compositions comprising the same MEDIMMUNE ONCOLOGY, INC. 2002-08-08 — — US claimed
EP-1080079-A4 THERMALLY STABLE TRIMETREXATES AND PROCESSES FOR PRODUCING THE SAME US BIOSCIENCE (US) 2001-10-04 — — EP claimed
US-6258952-B1 CRYSTALLIZATION MEDIMMUNE ONCOLOGY, INC. 2001-07-10 — — US claimed
EP-1080079-A1 THERMALLY STABLE TRIMETREXATES AND PROCESSES FOR PRODUCING THE SAME U.S. BIOSCIENCE, INC. (US) 2001-03-07 — — EP claimed
WO-1999059981-A1 THERMALLY STABLE TRIMETREXATES AND PROCESSES FOR PRODUCING THE SAME U.S. BIOSCIENCE, INC. (US) 1999-11-25 — — WO claimed
EP-4731689-A1 METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE Covestro Deutschland AG (DE) 2026-04-29 — — EP disclosed
EP-4200351-B1 METHOD FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2025-11-19 — — EP disclosed
EP-4200353-B1 METHOD FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2025-11-19 — — EP disclosed
EP-4448605-B1 PROCESS FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2025-11-19 — — EP disclosed
EP-4200352-B1 METHOD FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2025-11-19 — — EP disclosed
WO-1989004307-A1 SUBSTITUTED QUINAZOLINONES AS ANTICANCER AGENTS WARNER-LAMBERT COMPANY (US) 1989-05-18 — — WO disclosed
EP-0313974-A1 N-substituted derivatives of 1-desoxynojirimycine and 1-desoxymannonojirimycine, process for their preparation and their use as pharmaceuticals BAYER AG (DE) 1989-05-03 — — EP disclosed
EP-0277725-A2 4-Aryl-N-[2-(dialkylamino and heterocyclicamino) alkyl]-1-piperazinecarboxamides and their use as anti allergy agents A.H. ROBINS COMPANY, INCORPORATED (US) 1988-08-10 — — EP disclosed
EP-0252524-A2 Aryl- and aralkylamide- derivatives of Omega- (substituted-phenyloxy)-alkanoic acids as inhibitors of acyl-coa: cholesterol acyltransferase and pharmaceuticals containing them WARNER-LAMBERT COMPANY (US) 1988-01-13 — — EP disclosed
US-4102885-A Process for preparing 2,4-dihaloquinazolines BRISTOL-MYERS COMPANY (US) 1978-07-25 — — US disclosed
US-4016263-A BACTERICIDES BOEHRINGER INGELHEIM GMBH (DT) 1977-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199694-A1 Thermally stable trimetrexates and processes for producing the same TYMS, TYMP, TOP1 IDO1 1295/4885EP300 4399/4885KAT8 4475/4885
US-20020107393-A1 Tremextrexate derivatives and pharmaceutical compositions comprising the same TYMP, TYMS, DTYMK IDO1 513/4885EP300 4702/4885KAT8 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.